© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
April 25, 2021
All patients treated with 2.5 benzoyl peroxide and a stabilized cosmetic retinol saw significant improvement in lesion count reduction after 12 weeks.
Implementing alternative therapies does not mean abandoning conventional medications, stresses Peter Lio, MD. There must be a balance that works for the patient's situation.
April 24, 2021
Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.
Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.
New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.
The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.
A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.
Patients who received ixekizumab achieved PASI 90 at a median of 43.0 days and PASI 100 at 85.0 days.
In a Q&A, Peter Lio, MD, discusses some evidence for using integrative therapies with patients.
April 23, 2021
A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.